01/04/2020
Experimental Mesenchymal Stromal Cell therapy ImmunoARTTM has the potential to reduce ARDS (Acute Respiratory Distress Syndrome) caused COVID-19:
I would like to introduce a novel therapy of reducing inflammation within the tissues of the lungs of patients fighting the COVID-19 virus.
In the current stages the task of quickly reaching the right people with the right information is not easy. This is why our team is dedicated to innovative healthcare.
First “Compassionate trials" are running in Italy and Serbia.
Dr Miomir Knezevic CEO of EDUCELL (www.educell.si ) & Dr Marco Traub CEO of Trans European Stem Cell Therapy Society - TESCT (www.tesct.org ) are the leading global teams working on experimental Mesenchymal Stromal Cell therapy (ImmunoARTTM), which has the potential to reduce ARDS caused by COVID-19. EDUCELL is a biotech company founded in 1997; which had started with an emphasis in cell therapies. The company is devoted to bringing effective cell treatments to patients by providing effective and cost efficient products.
EDUCELL, through its strong clinical connections has developed an array of medical devices and cell products, which have been proven valuable in clinical use. Visit www.educell.si to know more.
The Trans European Stem Cell Therapy Society (TESCT ) was founded in 2005 by Dr. Marco Traub PHD in Switzerland to encourage the speedy transfer of Stem Cell technology from laboratory translation to clinical practice with a focus on the patient and the improvement of the Life Quality.
Visit www.tesct.org to know more.
The Swiss Clinic - www.theswissclinic.online
360 Health - www.360healthinc.com
